Page 41 - 2022_01-Haematologica-web

Recent developments for patients with R/R FL
plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, ran- domised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678-689.
54.Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36(23):2405-2412.
55. Hu N, Wang F, Sun T, et al. Follicular lym- phoma–associated BTK mutations are Inactivating resulting in augmented AKT activation. Clin Cancer Res. 2021;27(8):2301-2313.
56. Fowler NH, Coleman M, Stevens DA, et al. Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). J Clin Oncol. 2018;36(15_suppl):7549-7549.
57. Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzum- ab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4(19):4802-4811.
58. Bennani NN, LaPlant BR, Ansell SM, et al. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017;92(5):448- 453.
59. Smith SM, Besien K van, Karrison T, et al. Temsirolimus has activity in non–mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740-4746.
60. Davids MS, Roberts AW, Kenkre VP, et al. Long-term follow-up of patients with relapsed or refractory non–Hodgkin lym- phoma treated with venetoclax in a phase I, first-in-human study. Clin Cancer Res. 2021;27(17):4690-4695.
61. Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without ben- damustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628.
62. Blombery P, Birkinshaw RW, Nguyen T, et al. Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. Br J Haematol. 2019 186(6):e188-191.
63. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open- label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433-1442.
64. Ribrag V, Kim WS, Bouabdallah R, et al. Safety and efficacy of abexinostat, a pan-his- tone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017;102(5):903-909.
65. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non- Hodgkin’s lymphoma and mantle cell lym- phoma. J Clin Oncol. 2011;29(9):1198-1203.
66. Ogura M, Ando K, Suzuki T, et al. A multi- centre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014;165(6):768-776.
67. Evens AM, Balasubramanian S, Vose JM, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lym- phoma. Clin Cancer Res. 2016;22(5):1059- 1066.
68. Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rit-
uximab in relapsed diffuse large B-cell lym-
phoma. Blood. 2016;128(2):185-194.
69. Heward JA, Koniali L, D’Avola A, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138(5):
370-381.
70.Kahl BS, Hong F, Williams ME, et al.
Rituximab extended schedule or re-treat- ment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014;32(28):3096-3102.
71. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing obinu- tuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B- cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467-3474.
72. Leonard JP, Trneny M, Izutsu K, et al. AUG- MENT: a phase III study of lenalidomide plus rituximab versus placebo plus ritux- imab in relapsed or refractory indolent lym- phoma. J Clin Oncol. 2019;37(14):1188- 1199.
73. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135-3143.
74. Johnston A, Bouafia-Sauvy F, Broussais- Guillaumot F, et al. Retreatment with ritux- imab in 178 patients with relapsed and refractory B-cell lymphomas: a single institu- tion case control study. Leuk Lymphoma. 2010;51(3):399-405.
75. Maloney DG, Ogura M, Fukuhara N, et al. A phase 3 randomized study (HOMER) of ofa- tumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv. 2020;4(16):3886-3893.
76. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can
patients (pts) with relapsed/refractory indo- lent non-Hodgkin lymphoma (R/R iNHL). J Clin Oncol. 2020;38(15_suppl):8008.
83. Jacobson CA, Chavez JC, Sehgal A, et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non- Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20– containing chemoimmunotherapy (POD24). J Clin Oncol. 2021;39(15_suppl):7515.
84.Ghione P, Patel A, Bobillo S, Deighton K, Jacobson C, Nahas M. A comparison of clin- ical outcomes from ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR- 5 external control cohort in relapsed/refrac- tory follicular lymphoma (R/R FL). European Hematology Association Congress. 2021.
85. Fowler NH, Dickinson M, Dreyling M, et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory fol- licular lymphoma: interim analysis of the phase 2 Elara trial. Blood. 2020;136(Suppl 1):1-3.
86. Qualls D, Salles GA. Optimizing CAR T cell therapy in lymphoma. Hematol Oncol. 2021;39 (Suppl 1):104-112.
87.Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and ritux- imab (BR) in relapsed/refractory (r/r) FL and DLBCL. J Clin Oncol. 2018;36(15_suppl): 7507.
be repaired with for the tumor immunotherapy. 4720.
77. Chiu H, Trisal
Combination
immunotherapy
immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019;185(2):240-253.
78. Vo DN, Alexia C, Allende-Vega N, et al. NK cell activation and recovery of NK cell sub- sets in lymphoma patients after obinu- tuzumab and lenalidomide treatment. Oncoimmunology. 2018;7(4):e1409322.
79. Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalido- mide for relapsed or refractory follicular B- cell lymphoma (GALEN): a multicentre, sin- gle-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429-437.
80. Ghosh N, Salles GA, Lossos IS, et al. Obinutuzumab (G)-atezolizumab (atezo)- lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lym- phoma (FL): final analysis of a phase Ib/II trial. J Clin Oncol. 2021;39(15_suppl):7511.
81. Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refrac- tory B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1266-1272.
82. Jacobson CA, Chavez JC, Sehgal AR, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in
88.
89.
90.
91.
Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refrac- tory diffuse large B-cell lymphoma (LOTIS- 2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790- 800.
Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lym- phoma: final results from a phase 2 ran- domised study (ROMULUS). Lancet Haematol. 2019;6(5):e254-265.
Diefenbach C, Kahl BS, Banerjee L, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: pri- mary analysis of the full efficacy population in a phase Ib/II trial. Blood. 2019;134 (Suppl_1):126.
Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncas- tuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137 (19):2634-2645.
lenalidomide: Implications microenvironment and Blood. 2009;114(21):4713-
P, Bjorklund C, et al. lenalidomide-rituximab activates anti-tumour
92.Assouline SE, Kim WS, Sehn LH, et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(Suppl 1):42-44.
93. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20- targeting T-cell–engaging bispecific anti- body, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959- 1970.
94. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritam- ab in patients with relapsed or refractory B- cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;6736(21):1-13.
95. Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with
haematologica | 2022; 107(1)
33